NUVO PROVIDES UPDATE ON TRIAL FOR PENNSAID

Nuvo Research has completed an initial analysis of the data in its Phase III long-term, open-label safety trial for Pennsaid. A full review of the data is currently underway.

The trial involved more than 300 patients who were administered Pennsaid for 26 weeks and a subset of more than 100 of these patients who were administered the drug for a total of 52 weeks. Pennsaid is a topical non-steroidal anti-inflammatory used for the treatment of osteoarthritis and is currently approved for sale in Canada and several European countries.